Avadel Pharmaceuticals plc (AVDL) NASDAQ
21.64
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
21.64
+0(+0.00%)
Currency In USD
| Previous Close | 21.64 |
| Open | 21.64 |
| Day High | 21.64 |
| Day Low | 21.64 |
| 52-Week High | 23.57 |
| 52-Week Low | 6.38 |
| Volume | 35.02M |
| Average Volume | 2.42M |
| Market Cap | 2.12B |
| PE | -1,082 |
| EPS | -0.02 |
| Moving Average 50 Days | 21.5 |
| Moving Average 200 Days | 15.49 |
| Change | 0 |
Data not available
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing
GlobeNewswire Inc.
Feb 10, 2026 9:05 PM GMT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Avade
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes
GlobeNewswire Inc.
Jan 12, 2026 9:05 PM GMT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Avade
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
- Data expected in Q2 2026 - DUBLIN, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced the completion of patient enrollment in RE